Success Metrics

Clinical Success Rate
60.0%

Based on 3 completed trials

Completion Rate
60%(3/5)
Active Trials
2(25%)
Results Posted
100%(3 trials)
Terminated
2(25%)

Phase Distribution

Ph phase_3
5
63%
Ph phase_1
2
25%
Ph phase_2
1
13%

Phase Distribution

2

Early Stage

1

Mid Stage

5

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
2(25.0%)
Phase 2Efficacy & side effects
1(12.5%)
Phase 3Large-scale testing
5(62.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

2

trials recruiting

Total Trials

8

all time

Status Distribution
Active(2)
Completed(3)
Terminated(2)
Other(1)

Detailed Status

Completed3
Terminated2
Recruiting2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
2
Success Rate
60.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (25.0%)
Phase 21 (12.5%)
Phase 35 (62.5%)

Trials by Status

unknown113%
terminated225%
completed338%
recruiting225%

Recent Activity

2 active trials
Showing 5 of 8
recruitingphase_3

Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.

NCT04898283
recruitingphase_3

Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites

NCT04435990
terminatedphase_3

Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis

NCT04874714
unknownphase_3

Efficacy and Safety Evaluation for the Treatment of HDM Induced Allergic Asthma and Rhinitis/Rhinoconjunctivitis

NCT05400811
completedphase_1

A Study of LY3016859 in Healthy Volunteers

NCT01545583
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT04898283Phase 3

Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.

Recruiting
NCT04435990Phase 3

Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites

Recruiting
NCT04874714Phase 3

Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis

Terminated
NCT05400811Phase 3

Efficacy and Safety Evaluation for the Treatment of HDM Induced Allergic Asthma and Rhinitis/Rhinoconjunctivitis

Unknown
NCT01545583Phase 1

A Study of LY3016859 in Healthy Volunteers

Completed
NCT02681861Phase 1

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP6294 Administered Intravenously or Subcutaneously in Healthy Young Male and Female Subjects

Completed
NCT01126580Phase 3

A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3)

Completed
NCT01018810Phase 2

A Study for Adults With Plaque Psoriasis

Terminated

All 8 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
8